Zobrazeno 1 - 10
of 253
pro vyhledávání: '"5-aminosalicylate"'
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract A 26‐year‐old man with a history of ulcerative colitis treatment presented to our clinic with abdominal pain and fever. He had a history of bloody stools and abdominal pain at 19 years of age. A thorough examination by a medical practiti
Externí odkaz:
https://doaj.org/article/d91f15e4926642459c9606ba34d3aeea
Autor:
Yoshihiro Noguchi, Shuji Yamashita, Hirofumi Tamaki, Arihiro Osanai, Yoko Ino, Tomoya Tachi, Kazuhiro Iguchi, Hitomi Teramachi
Publikováno v:
Pharmacoepidemiology, Vol 2, Iss 1, Pp 26-34 (2023)
Although 5-Aminosalicylate (5-ASA) has been shown to act on the local mucosa, when 5-ASA is orally administered, most of it is absorbed in the upper gastrointestinal tract and does not reach the large intestine, where lesions are present. Therefore,
Externí odkaz:
https://doaj.org/article/b9d94b0418624537bc9a1cb194974d70
Autor:
E. P. Sivolodskii, O. A. Freylikhman
Publikováno v:
Инфекция и иммунитет, Vol 9, Iss 5-6, Pp 648-654 (2020)
The aim of the study was to identify an optimal research target for detection of Klebsiella michiganensis isolates, determine their genetic and phenotypic characteristics necessary for identification. Here, we examined 11 Klebsiella oxytoca strains,
Externí odkaz:
https://doaj.org/article/b338be6473ae46e1b9860d36b88f966c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Pharmacoepidemiology. 2(1):26-34
Autor:
Jakob Vrus, Nikolina Bašić Jukić
Publikováno v:
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)REFERENCES. 43(1)
Inflammatory bowel diseases are autoimmune disorders affecting the gastrointestinal tract and producing a wide variety of extraintestinal manifestations. Kidneys are a rare target organ of their extraintestinal activity, but if affected, renal functi
Background & Aims: The dose and duration of mesalazine treatment for ulcerative colitis (UC) is a potentially important determinant of effectiveness, with evidence suggesting that continuing the induction dose for 6-12 months may improve outcomes; ho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::19561b3db109fdec57f24f7e75bf676c
Autor:
West, R., Russel, M., Bodelier, A., Kuijvenhoven, J., Bruin, K., Jansen, J., Meulen, A. van der, Keulen, E., Wolters, L., Ouwendijk, R., Bezemer, G., Koussoulas, V., Tang, T., Dobbenburgh, A. van, Nistelrooy, M. van, Minderhoud, I., Vandebosch, S., Lubbinge, H.
Publikováno v:
Journal of Gastrointestinal and Liver Diseases, 31(1), 18-24. MEDICAL UNIV PRESS
Background and Aims: The dose and duration of mesalazine treatment for ulcerative colitis (UC) is a potentially important determinant of effectiveness, with evidence suggesting that continuing the induction dose for 6-12 months may improve outcomes;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0722d124b3ebdecdda2203dde8fc24ec
https://doi.org/10.15403/jgld-3927
https://doi.org/10.15403/jgld-3927
Autor:
Trevor L. Schell, Luke J. Richard, Katharine Tippins, Rachel K. Russ, Mary S. Hayney, Freddy Caldera
Publikováno v:
Clinical Gastroenterology and Hepatology
Coronavirus disease 2019 (COVID-19) vaccines are recommended for all patients with inflammatory bowel disease (IBD).
Publikováno v:
Gut
Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients an